| Ytd | -34.71% | |
| 1y | 84.54% |
| Open | 6.15 | Prev Close | 6.07 | Low | 5.82 | High | 6.18 | Mkt Cap | 2.05B |
| Vol | 4.43M | Avg Vol | 6.84M | EPS | -0.44 | P/E | N/A | Forward P/E | -389.67 |
| Beta | 1.53 | Short Ratio | 9.88 | Inst. Own | 67.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-02 | 50-d Avg | 6.42 | 200-d Avg | 5.91 | 1yr Est | 13.10 |
NUVB News
Nuvation Bio (NUVB) stock jumps 6% after early FDA label update for IBTROZI, highlighting over 4 yea
Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 monthsNo changes t
Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 months No changes
Citizens analyst Silvan Turkcan reiterates Nuvation Bio (NYSE:NUVB) with a Market Outperform and
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main
Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Tran
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, includi
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, includi
Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Nuvation Bio Inc. (NYSE:NUVB) is a “pure spec
Cramer calls Nuvation Bio a pure spec, prefers CoreWeave over IREN, is unsure on Seneca, cautious on
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nu
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company fo
Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is ref
Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings
Wall Street analysts upgraded Parsons Corp, InnovAge Holding Corp, Equifax Inc, and initiated covera
Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO
Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safu
Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safu
The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock.
JP Morgan analyst Priyanka Grover initiates coverage on Nuvation Bio (NYSE:NUVB) with a Overweigh
Nuvation Bio (NYSE: NUVB - Get Free Report) and Pathfinder Cell Therapy (OTCMKTS:PFND - Get Free Rep
Nuvation Bio NYSE: NUVB reported second-quarter total revenue of $31.7 million, including $23.2 mill
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and rais
Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.15 per share in line with the Zacks Co
Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product
Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.18) per share which beat the analyst conse
Presentations Overview:WCLCTitle: Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Smal
Analyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key pati
Medical sector earnings are off to a strong start, and four biotech companies are positioned to pote
Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings
The consensus price target hints at a 94.3% upside potential for Nuvation Bio (NUVB). While empirica
HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and ra
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main
NEW YORK, July 22, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global on
Nuvation Bio reports positive long-term Phase 2 safusidenib data for glioma patients and expands its
U.S. stocks saw mixed results, with Nasdaq up 150 points. AMC shares rose after beating earnings exp
Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progressi
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowe
Truist Securities analyst Gregory Renza maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises
U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release a
Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tacklin
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest ch
RBC Capital analyst Leonid Timashev reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and mai
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main
HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and m
Nuvation Bio (NYSE:NUVB) reported quarterly earnings of $0.01 per share which met the analyst consen
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest ch